* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Slide 1
Survey
Document related concepts
Transcript
600 Hypnotics association with Mortality Charles Heaney 19/02/2013 BMJ • Volume 2, Issue 1, 2012 Cohort Study matching 10,500 patient’s (mean age of 54) who were prescribed hypnotics with 23,500 matched controls and followed them for 2.5 years. Outcome • Clear association between patient’s prescribed any hypnotic, and higher risk of death, even at low doses • Risks were elevated for different hypnotics including benzodiazepines, barbituates, and anti-histamines, and each was associated with an increased rate of death Association with Cancer • Also, there is an increased association with cancer with hypnotic use in the upper third • Author claims results were robust within groups suffering each co-morbidty indicating that the hazard was not attributable to pre-existing disease. Conclusion • Receiving hypnotic prescriptions is associated with greater then threefold increase in hazard of death, even when prescribed less then 18 pills per year BJGP 2011 • 61:558 Systemic review of RCT’s of minimal intervention’s • Sending a brief letter • Self Help Information • Consultation with a G.P. • All of these explained concern over long term use, their potential side affects, and advise on gradual dose reduction Results • NNT, showed that for every 12 older people who receive a letter, one will cease Benzodiazepine use. Epidemiology • 50% of patient who attend primary care have insomnia • 30-40% of the population Co-exisiting • 50% had Depression • 48% had Anxiety • 43% had General Physical Health Problems • 22% Restless Leg Syndrome • 9% had Obstructive Sleep Apnoea • 12% had ethanol and substance missuse • 12% have Primary Insomnia • 2% have Delayed Sleep Phase Disorder Outcome • All three methods found a twice a reduction in benzodiapines compared to control groups • NNT, 12 letters to older people need to receive one letter for one to cease benzodiazepines. General Approach • Treatment for any underlying medical condition, psychiatric illness, and substance abuse. • Behavioural Therapies • Medications • Combination therapy Sleep Hygiene • Sleep as long as to get rested and then get out of bed • External Stimuli • Regular Sleep Cycle • Try not to force sleep • Avoid caffeinated beverages after lunch • Avoid smoking, particularly in the evening Stimulus Control • Bed is primarily for sleeping Sleep Restriction Therapy • Some patient’s stay in bed longer to make up for lost sleep Contraindications to meds • • • • • • Pregnancy Alcohol consumption Renal or hepatic disease Pulmonary disease or sleep apnea Night time decision makers Older Patients Hypnotic Drugs • Shorter Acting Drugs, such as Zolpidem are preferred for insomnia with delayed sleep latency • Medium Acting, such as Zopiclone and Temazepam, if they wake at night • Long Acting, such as Clonazepam, if they have insomnia with day time anxiety • Advise max 3 times a week Antidepressants • Sedating anti-depressants have not have problems with dependence, there is less evidence of eifficacy and side affects • Antipsychotics • Barbiturates • Herbal Products Adverse Affect • sedation, drowsiness, dizziness, lightheadedness, cognitive impairment, motor incoordination, and dependence • habit forming and rebound insomnia may occur when some short-acting medications are discontinued. • Older Patient’s, threefold increase in hazards of death, even when less then 18 pills per year • In March of 2007, the FDA requested that the manufacturers of sedative-hypnotic medications strengthen their labeling to include stronger language about the risks of severe allergic reactions and complex sleep-related behaviors (eg, driving, making telephone calls, eating, having sex while not fully awake). Ciracdian Rythem Disorders • • • • Phototherapy Chronotherapy Cirrhosis Jet Lag • Speed of onset — The most important distinction among the benzodiazepines, in the context of abuse potential, is the speed of onset . • Drugs that more rapidly reach peak brain levels after oral administration are relatively more likely to produce brain reward or euphoria, and are therefore more likely to be abused. Withdrawal • • • • • • • • Increased body temperature Elevated blood pressure Increased respiratory rate and heart rate Aroused level of consciousness or frank delirium Tremulousness Increased reflexes Disorientation Psychotic behavior including hallucinations